September 20, 2023
Daiichi Sankyo said on September 15 that it has gained the blessing of a European regulatory panel for its antibody drug conjugate Enhertu (trastuzumab deruxtecan) for the second-line treatment of HER2 mutated non-small cell lung cancer (NSCLC). The European Medicines...read more